A drug used alone or with other drugs to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom macroglobulinemia (a type of non-Hodgkin lymphoma), mantle cell lymphoma, or marginal zone lymphoma. It is also being studied in the treatment of other types of cancer. Ibrutinib blocks a protein called BTK, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Imbruvica. US Brand Name(s)Imbruvica
Are you looking for or in search of FDA approved “ibrutinib tablets, for oral use in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Leukemia treatment. Need Access of “ibrutinib tablets, for oral use, get in touch with our healthcare professional.
Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton’s tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.[
Ibrutinib is approved to treat:
- Chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is used alone or with other drugs.
- Mantle cell lymphoma in adults who have received at least one other treatment.
- Marginal zone lymphoma. It is used in adults who have received at least one other CD20-targeted therapy.
- Waldenström macroglobulinemia (a type of non-Hodgkin lymphoma) in adults.
Ibrutinib is also being studied in the treatment of other types of cancer.